Defunct Company
Total Trials
2
As Lead Sponsor
As Collaborator
0
Total Enrollment
53
NCT02762084
Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients
Phase: Phase 2
Role: Lead Sponsor
Start: Jun 6, 2016
Completion: Apr 24, 2017
NCT02828111
Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas
Start: Nov 11, 2016
Completion: Nov 9, 2017